Related Experiment Video
Updated: Feb 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Multiple biomarkers covering distinct pathways for predicting outcomes after ischemic stroke
Chongke Zhong1, Zhengbao Zhu1, Aili Wang1
1From the Department of Epidemiology (C.Z., Z.Z., A.W., Tan Xu, X.B., H.P., J.Y., L.H., Tian Xu, Y.Z.), School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou, China; Department of Epidemiology (C.Z., J.C., J.H.), Tulane University School of Public Health and Tropical Medicine, New Orleans, LA; Department of Epidemiology (J.Y.), School of Public Health, Guizhou Medical University, Guiyang; Department of Preventive Medicine (L.H.), Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, China; Department of Medicine (J.C., J.H.), Tulane University School of Medicine, New Orleans, LA; Department of Neurology (Tian Xu), Affiliated Hospital of Nantong University, Nantong; Department of Neurology (Y.P.), Affiliated Hospital of North China University of Science and Technology; Department of Neurology (J.W.), Yutian County Hospital, Tangshan; Department of Epidemiology (Q.L.), School of Public Health, Taishan Medical College, Taian; Department of Neurology (Z.J.), Kerqin District First People's Hospital of Tongliao City, Tongliao; and Department of Neurology (D.G.), Affiliated Hospital of Xuzhou Medical College, Xuzhou, China.
Insights
Combining multiple novel biomarkers significantly improves risk prediction for adverse outcomes in ischemic stroke patients, including death, disability, and vascular events.
Area of Science:
- Neurology
- Biomarker Discovery
- Cardiovascular Research
Background:
- Ischemic stroke poses a significant global health burden, necessitating improved prognostic tools.
- Current risk stratification models for stroke outcomes often lack precision.
- Novel biomarkers may offer enhanced predictive capabilities for post-stroke complications.
Purpose of the Study:
- To evaluate the combined prognostic value of multiple novel biomarkers in predicting outcomes after acute ischemic stroke.
- To assess the impact of incorporating these biomarkers into existing risk prediction models.
Main Methods:
- Analysis of data from 3,405 participants in the China Antihypertensive Trial in Acute Ischemic Stroke.
- Measurement of 12 informative biomarkers, with a focus on high-sensitive C-reactive protein, complement C3, matrix metalloproteinase-9, hepatocyte growth factor, and antiphosphatidylserine antibodies.
- Multivariable analyses to determine associations with primary (death/major disability) and secondary outcomes (major disability, death, vascular events) at 3 months.
Main Results:
- Elevated levels of specific biomarkers (hs-CRP, C3, MMP-9, HGF, anti-PS antibodies) were individually linked to adverse outcomes.
- A dose-dependent relationship was observed: participants with more elevated biomarkers showed significantly increased risks.
- Individuals with 5 elevated biomarkers had substantially higher odds of the primary outcome (aOR 3.88), major disability (aOR 2.81), death (aOR 5.67), and vascular events (aOR 4.00).
Conclusions:
- A clear gradient exists between the number of elevated novel biomarkers and the risk of major disability, mortality, and vascular events post-stroke.
- Integrating a panel of these biomarkers significantly enhances risk stratification for adverse outcomes in ischemic stroke patients.
- These findings support the clinical utility of multi-biomarker panels for improved stroke outcome prediction.
Objective:
To study the prognostic significance of multiple novel biomarkers in combination after ischemic stroke.
Methods:
We derived data from the China Antihypertensive Trial in Acute Ischemic Stroke, and 12 informative biomarkers were measured. The primary outcome was the combination of death and major disability (modified Rankin Scale score ≥3) at 3 months after ischemic stroke, and secondary outcomes included major disability, death, and vascular events.
Results:
In 3,405 participants, 866 participants (25.4%) experienced major disability or died within 3 months. In multivariable analyses, elevated high-sensitive C-reactive protein, complement C3, matrix metalloproteinase-9, hepatocyte growth factor, and antiphosphatidylserine antibodies were individually associated with the primary outcome. Participants with a larger number of elevated biomarkers had increased risk of all study outcomes. The adjusted odds ratios (95% confidence intervals) of participants with 5 elevated biomarkers were 3.88 (2.05-7.36) for the primary outcome, 2.81 (1.49-5.33) for major disability, 5.67 (1.09-29.52) for death, and 4.00 (1.22-13.14) for vascular events, compared to those with no elevated biomarkers. Simultaneously adding these 5 biomarkers to the basic model with traditional risk factors led to substantial reclassification for the combined outcome (net reclassification improvement 28.5%, p < 0.001; integrated discrimination improvement 2.2%, p < 0.001) and vascular events (net reclassification improvement 37.0%, p = 0.001; integrated discrimination improvement 0.8%, p = 0.001).
Conclusion:
We observed a clear gradient relationship between the numbers of elevated novel biomarkers and risk of major disability, mortality, and vascular events. Incorporation of a combination of multiple biomarkers observed substantially improved the risk stratification for adverse outcomes in ischemic stroke patients.
Related Concept Videos
Predicting Reaction Outcomes
Predicting Molecular Geometry
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...

